Boehringer Ingelheim Licenses BaroFold's PreEMT High-Pressure Protein-Refolding Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Boehringer Ingelheim Licenses BaroFold's PreEMT High-Pressure Protein-Refolding Technology


Pharmaceutical Technology Europe

Boehringer Ingelheim has entered into a non-exclusive technology and commercial license option agreement with BaroFold. Under the terms of the agreement, Boehringer Ingelheim will license BaroFold's pressure-enabled manufacturing technology (PreEMT). A laboratory-scale reactor of the PreEMT high-pressure protein-refolding technology will be installed at Boehringer Ingelheim's microbial facility in Vienna, Austria. The technology will be used for the development of biopharmaceutical production processes.

PreEMT uses high pressure to disaggregate and control the refolding of recombinant proteins to their native structures at yields and efficiencies that cannot be achieved with existing technologies. PreEMT can substantially reduce the cost of manufacturing because of its increased yield and throughput at high protein concentrations. The technology is readily scalable and has been used for the cGMP production of clinical materials for Phase I to Phase III trials.

Georg Klima, executive director of Process Science Austria at Boehringer Ingelheim, said in a press statement, "This collaboration builds upon the exciting work we have completed with BaroFold over the last 18 months and enhances our strategy to integrate the most innovative technologies for biologic manufacturing. We will be able to leverage BaroFold's high pressure refold technology on a variety of proteins under development at our facility in Vienna."

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology Europe,
Click here